Literatur
- 1
Mountain C.
Revisions in the international system for staging lung cancer.
Chest.
1997;
111
1710-1717
- 2
Thomas M, Gatzemeier U, Goerg R, Matthiessen W, Morr H, Schönfeld N, Ukena D, Stamatis G.
Empfehlungen zur Diagnostik des Bronchialkarzinoms.
Pneumologie.
2000;
54
361-371
- 3
Pignon J P, Arriagada R, Ihde D C, Johnson D H, Perry M C, Souhami R L, Brodin O,
Joss R A, Kies M S, Lebeau B. et al .
A metaanalysis of thoracic radiotherapy for small cell lung cancer.
N Engl J Med.
1992;
327
1618-1624
- 4
Warde P, Payne D.
Does thoracic irradiation improve survival and local control in limited-stage small-cell
carcinoma of the lung? A meta-analysis.
J Clin Oncol.
1992;
10
890-895
- 5
Murray N, Coy P, Pater J L, Hodson I, Arnold A, Zee B C, Payne D, Kostashuk E, Evans W,
Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K.
Importance of timing for thoracic irradiation in the combined modality treatment of
limited-stage small-cell lung cancer.
J Clin Oncol.
1993;
11
336-344
- 6
Jeremic B, Shibamoto Y, Acimovic L, Milisavlejevic S.
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent
chemotherapy in limited small-cell lung cancer. A randomized study.
J Clin Oncol.
1997;
15
893-899
- 7
Goto K, Nishiwaki Y, Takada M, Fukuoka M, Kawahara M, Sugiara T, Kurita Y, Watanabe K,
Noda K, Yoshimura K, Tamura T, Saijo N.
Final results of a phase-III-study of concurrent versus sequential thoracic radiotherapy
(TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small
cell lung cancer (LD-SCLC). The Japan Clinical Oncology Group (JCOG) Study.
Proc Am Soc Clin Oncol.
1999;
18
468a (abs. 1805)
- 8
Work E, Nielsen O, Bentzen S, Fode K, Palshof T.
Randomized study of initial versus late chest irradiation combined with chemotherapy
in limited-stage small-cell lung cancer.
J Clin Oncol.
1997;
15
3030-3037
- 9
Perry M, Eaton W, Propert K, Ware J, Zimmer B, Chahinian P, Skarin A, Carey R, Kreisman H,
Faulkner C, Comis R, Green M.
Chemotherapy with or without radiation therapy in limited small-cell lung cancer.
N Engl J Med.
1987;
316
912-918
- 10
Perry M, Herndon J, Eaton W, Green M.
Thoracic radiation therapy added to chemotherapy in limited small cell lung cancer:
an update of cancer and leukemia group B (CALGB) study 8083.
Proc Am Soc Clin Oncol.
1996;
15
384 (abs. 1150)
- 11
Turrisi A, Kim K, Blum R, Sause W T, Livingston R B, Komaki K, Wagner H, Aisner S,
Johnson D.
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung
cancer treated concurrently with cisplatin and etoposide.
N Engl J Med.
1999;
340
265-271
- 12
Auperin A, Arriagada R, Pignon J P, Le Pechooux C, Gregor A, Stephens R J, Kristjansen P EG.
Prophylactic cranial irridiation for patients with small-cell lung cancer in complete
remission.
N Engl J Med.
1999;
341
476-484
- 13
Shepherd F A, Ginsberg R J, Patterson G A, Evans W K, Feld R.
A prospective study of adjuvant surgical resection after chemotherapy for limited
small-cell lung cancer. A University of Toronto Lung Oncology Group Study.
J Thorac Cardiovasc Surg.
1989;
97
177-186
- 14
Davis S, Crino L, Tonato M, Darwish S, Pelicci P G.
A prospective analysis of chemotherapy following surgical resection of clinical stage
I - II small-cell lung cancer.
Am J Clin Oncol.
1993;
16
93-95
- 15
Karrer K, Shields T W, Denck H, Hrabar B, Vogt-Moykopf I, Salzer G M.
The importance of surgical and multimodality treatment for small-cell bronchial carcinoma.
J Thorac Cardiovasc Surg.
1989;
97
168-176
- 16
Kaiser D, Fritzsche A, Matthiessen W.
Operationsindikation beim kleinzelligen Bronchialkarzinom.
Dtsch Med Wochenschr.
1992;
117
103-106
- 17
Jeremic B, Shibamoto Y, Nicolic N, Milicic B, Milisavljevic S, Dagovic A, Aleksandrovic J,
Radosavljevid-Asic G.
Role of radiation therapy in the combined-modality treatment of patients with extensive
disease small-cell lung cancer: a randomized study.
Journal of Clinical Oncology.
1999;
17
2092-2099
- 18
Pearson F G, De Larue N C, Ilves R, Todd T R, Cooper J D.
Significance of positive superior mediastinal nodes identified at mediastinoscopy
in patients with resectable cancer of the lung.
J Thorac Cardiovasc Surg.
1982;
83
1-11
- 19
Pitz C C, Brutel-de I R, Elbers H R, Westermann C J, van den Bosch J.
Surgical treatment of 125 patients with non-small cell lung cancer and chest wall
involvement.
Thorax.
1996;
51
846-850
- 20
Gould P M, Bonner J A, Sawyer T E, Deschamps C, Lange C M, Li H.
Patterns of failure and overall survival in patients with completely resected T3 N0
M0 non-small cell lung cancer.
Int J Radiat Oncol Biol Phys.
1999;
45
91-95
- 21
Paulson D L.
The role of preoperative radiation therapy in the surgical management of cacinoma
in the superior pulmonary sulcus.
Front Radiat Ther Oncol.
1970;
5
177-187
- 22
Ahmad K, Fayos J V, Kirsh M M.
Apical lung carcinoma.
Cancer.
1984;
54
913-917
- 23
Attar S, Krasna M J, Sonett J R, Hankins J R, Slawson R G, Suter C M, McLaughlin J S.
Superior sulcus (Pancoast) tumor: experience with 105 patients [see comments].
Ann Thorac Surg.
1998;
66
193-198
- 24
Paulson D L.
Carcinomas in the superior pulmonary sulcus.
J Thorac Cardiovasc Surg.
1975;
70
1095-1104
- 25
Maggi G, Casadio C, Pischedda F, Giobbe R, Cianci R, Ruffini E, Molinatti M, Mancuso M.
Combined radiosurgical treatment of Pancoast tumor.
Ann Thorac Surg.
1994;
57
198-202
- 26 Stuschke M, Heilmann H P. Lunge und Mediastinum. In: Scherer E, Sack H (Hrsg).
Strahlentherapie, 4. Aufl. Berlin: Springer 1996: 683-718
- 27
Arcasoy S M, Jett J R.
Superior pulmonary sulcus tumors and pancoast syndrome.
N Engl J Med.
1997;
337
1370-1376
- 28
Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, Katsuda Y.
Is T factor of the TNM staging system a predominat prognostic factor in pathologic
stage I non-small cell lung cancer?.
J Thorac Cardiovasc Surg.
1993;
106
90-94
- 29
Mountain C.
New prognostic factors in lung cancer.
Chest.
1995;
108
246-254
- 30
Cote R J, Beattie E J, Chaiwun B, Shi S R, Harvey J, Chen S C, Sherrod A E, Groshen S,
Taylor C R.
Detection of occult bone marrow micrometastases in patients with operable lung carcinoma.
Ann Surg.
1995;
222
415-425
- 31
Passlick B, Kubuschok B, Izbicki J R, Thetter O, Pantel K.
Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small
cell lung cancer.
Ann Thorac Surg.
1999;
68
2053-2058
- 32
Thomas M, Macha H N, Rübe C, van de Loo J.
Stellenwert der Chemotherapie in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms.
Dtsch med Wschr.
1995;
120
1627-1630
- 33
PORT. Meta-analysis Trialists Group .
Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis
of individual patient data from 9 randomized controlled trials.
Lancet.
1998;
352
257-263
- 34
Klages H T, Stuschke M.
Postoperative Radiotherapie beim kurativ resezierten nicht-kleinzelligen Bronchialkarzinom.
Strahlenther Onkol.
1999;
175
134-138
- 35
Rosell R, Gomez-Codina J, Camps C, Ryan M B, Putnam J B, Lee L S, Dhingra H, De Caro L,
Chasen M, McGavran M, Atkinson E N, KiHong W.
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone
in patients with non-small-cell lung cancer.
N Engl J Med.
1994;
330
153-158
- 36
Roth J, Fossela F, Komaki R, Ryan M B, Putnam J B, Lee L S, Dhingra H, De Caro L,
Chasen M, McGavran M, Atkinson E N, KiHong W.
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone
in resectable stage IIIA non-small-cell lung cancer.
J Natl Cancer Inst.
1994;
86
673-680
- 37
Albain K S, Rusch V W, Crowley J J, Rice T W, Turrisi A T, Weick J K, Lonchyna V A,
Presant C A, McKenna R J, Gandara D R, Fosmire H, Taylor S A, Stelzer K J, Beasley K R,
Livingston R B.
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages
IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology
Group phase II study 8805.
J Clin Oncol.
1995;
13
1880-1892
- 38
Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Müller M R,
Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S.
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated
accelerated radiotherapy and definitive surgery in locally advanced non-small-cell
lung cancer: mature results of a phase II trial.
J Clin Oncol.
1998;
16
622-634
- 39
Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha H N, Wagner W, Klinke F, Sheld H H,
Willich N, Berdel W E, Junker H.
Chemotherapy and subsequent twice-daily chemoradiation before surgery in stage III
non-small cell lung cancer: impact of tumor regression on survival.
J Clin Oncol.
1999 (a);
17
1185-1193
- 40
Thomas M, Rübe C, Semik M, Steppling H, Macha H, Deimling A, Klinke F, Deppermann K,
Clemens M, Dornoff W, Weber W, Berdel W.
Randomized trial of chemotherapy and twice-daily chemoradiation versus chemotherapy
alone before surgery in stage III non-small cell lung cancer: interim of toxicity.
Proc am Soc Clin Oncol.
1999 (b);
18
458a (abs. 1769)
- 41
Dillman R O, Seagren S L, Propert K J, Guerra J, Eaton W L, Perry M C, Carey R W,
Frei E F, Green M R.
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation
alone in stage III non-small-cell lung cancer.
N Engl J Med.
1990;
323
940-945
- 42
Le Chevalier T, Arriagda R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe Terrier M J,
Douillard J Y, Laplanche A.
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable
non-small cell lung cancer: First analysis of a randomized trial in 353 patients.
J Natl Cancer Inst.
1991;
83
417-423
- 43
Le Chevalier T, Arriagda R, Tarayre M, Lacombe Terrier M J, Laplanche A, Quoix E,
Ruffie P, Martin M, Douillard J Y.
Significant effect of adjuvant chemotherapy on survival in locally advanced non-small
cell lung carcinoma (letter).
J Natl Cancer Inst.
1992;
84
58
- 44
Sause W T, Scott C, Taylor S, Johnson D, Livingstone R, Komaki R, Emami B, Curran W J,
Byhardt R W, Turrisi A T, Dar A R, Cox J D.
Radiation Therapy Oncology Group (RTOG) 80-08 and Eastern Cooperative Oncology Group
(ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable
non-small cell lung cancer.
J Natl Cancer Inst.
1995;
87
198-205
- 45
Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W,
Byhardt R, Dar A, Turrisi A.
Final results of phase III trial in regionally advanced non-small cell lung cancer.
RTOG, ECOG and SWOG.
Chest.
2000;
117
358-364
- 46
Dillman R O, Herndon J, Seagren S L, Eaton W L, Green M R.
Improved survival in stage III non-small cell lung cancer: seven year follow up of
CALGB 8433 trial.
J Natl Cancer Inst.
1996;
88
1210-1215
- 47
American Society of Clinical Oncology .
Clinical practice guidelines for the treatment of unresectable non-small-cell lung
cancer.
J Clin Oncol.
1997;
15
2996-3018
- 48
Choi N, Baumann M, Flentje M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P.
Predictive factors of radiation response in non-small cell lung cancer: present status.
Lung Cancer.
2001;
31
43-56
- 49
Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M.
Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional
radiotherapy in non-small cell lung cancer: a randomised multicenter trial.
Lancet.
1997;
350
161-165
- 50
Schaake-Konig C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout H, van Houtte P,
Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L,
Sculier J P, van Zandwijk N, Bartelink H.
Effects of concomittand cisplatin and radiotherapy on inoperable non-small-cell lung
cancer.
N Engl J Med.
1992;
326
524-530
- 51
Jeremic B, Shibamoto L, Acimovic L, Djuric L.
Randomized trial of hyperfractionated radiation therapy with or without concurrent
chemotherapy for stage III non-small cell lung cancer.
J Clin Oncol.
1995;
13
452-458
- 52
Jeremic B, Shibamoto L, Acimovic L, Milisavljevic S.
Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide
for stage III non-small-cell lung cancer: a randomized study.
J Clin Oncol.
1996;
14
1065-1070
- 53
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y.
Phase III study of concurrent versus sequential thoracic radiotherapy in combination
with Mitomycin, Vindesine, and Cisplatin in unresectable stage III non-small lung
cancer.
J Clin Oncol.
1999;
17
2692-2699
- 54
Curran W, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wassermann T, Rosenthal S,
Byhardt R, Sause W, Cox J.
Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected
stage III non-small cell lung cancer: Initial report of Radiation Therapy Oncology
Group (RTOG) 9410.
Proc Am Soc Clin Oncol.
2000;
19
484a (abs. 1891)
- 55
Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M. (on behalf of the
CHART steering committee) .
Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional
radiotherapy in non-small-cell lung cancer: mature data from the randomised multicentre
trial.
Radiother Oncol.
1999;
52
137-148
- 56
Baumann M.
Accelerated radiation therapy in non-small cell lung cancer.
Radiother Oncol.
1999;
52
97-99
- 57
Baumann M, Appold S, Zips D, Nestele U, Petersen C, Herrmann Th.
Modified fractionation in the radical treatment of non-small cell lung cancer.
Front Radiat Ther Oncol.
2000;
34
80-88
- 58
Baumann M, Herrmann T, Matthiessen W, Koch R, Strelocke K, Paul U. für das CHARTWEL-Bronchus
Protokollkomitee (1997) CHARTWEL-Bronchus (ARO 97-1) .
Eine randomisiert-multizentrische Studie zum Vergleich einer konventionell fraktionierten
Strahlentherapie mit CHARTWEL-Bestrahlung bei inoperablen nicht-kleinzelligen Bronchialkarzinomen.
Strahlenther Onkol.
1997;
173
663-667
- 59
Thomas M.
Tumorassoziierte Prognoseparameter beim nicht-kleinzelligen Bronchialkarzinom.
Pneumologie.
1997;
51
669-677
- 60
Thomas M, Rübe C, Semik M, von Eiff M, Klinke F, Macha H N, Freitag L, Scheld H H,
Willich N, Berdel W E, Junker K.
Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence
by pretherapeutic assessment of p185neu.
Eur Respir J.
1999(c);
13
424-429
- 61
Non-small cell lung cancer collaborative group .
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomized clinical trials.
BMJ.
1995;
311
899-909
- 62
Le Chevalier T.
Chemotherapy for advanced non-small cell lung cancer.
Chest.
1996;
109
107s-109s
- 63
Ellis P A, Smith I, Hardy J, Nicolson M, Talbot D, Ashley S, Priest K.
Symptom relief with MVP (mitomycin C, vinblastin and cisplatin) chemotherapy in advanced
non-small cell lung cancer.
Br J Cancer.
1995;
71
366-370
- 64
Thatcher N, Niven R M, Anderson H.
Agressive versus nonaggressive therapy for metastatic non-small cell lung cancer.
Chest.
1996;
109
87s-92s
- 65
Wirbel R J, Mutschler W E.
Die chirurgische Therapie von Knochenmetastasen.
Zentralbl Chir.
1995;
120
707-715
- 66
Janjan N A.
Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals.
Cancer.
1997;
80
1628-1645
- 67 Sullivan F J. Palliative radiotherapy for lung cancer. In: Pass HI, Mitchell JB,
Johnson DH, Turrisi AT (ed). Lung Cancer. Principles and Practice. Philadelphia-New
York: Lippincott-Raven 1996: 775-789
- 68
Berenson J R, Lichtenstein A, Porter L, Dimopoulos M A, Bordoni R, George S, Lipton A,
Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma D, Heffernan M,
Seaman J, Knight R.
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple
myeloma.
N Engl J Med.
1996;
334
488-493
- 69
Hortobagyi G N, Theriault R L, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H,
Simeone J F, Seaman J, Knight R D.
Efficacy of pamidronate in reducing skeletal compliancations in patients with breast
cancer and lytic bone metastases.
N Engl J Med.
1996;
335
1785-1791
- 70
Theriault R L, Lipton A, Hortoagyi G N, Leff R, Glück S, Stewart J F, Costello S,
Kennedy I, Simeone J, Seaman J J, Knight R D, Mellars K, Heffernan M, Reitsma D J.
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic
bone lesions: A randomized, placebo-controlled trial.
J Clin Oncol.
1999;
17
846-854
- 71
Ryan G F, Ball D L, Smith J G.
Treatment of brain metastases from primary lung cancer.
Int J Radiat Oncol Biol Phys.
1995;
31
273-278
- 72
Patchell R A, Tibbs P A, Walsh J W, Dempsey R J, Maruyama Y, Kryscio R J, Markesbery W R,
Macdonald J S, Young B.
A randomized trial of surgery in the treatment of single metastases to the brain.
N Engl J Med.
1990;
322
494-500
- 73
Sause W T, Crowley J J, Morantz R, Rotman M, Mowry P A, Bouzaglou A, Borst J R, Selin H.
Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery + RT
versus RT alone.
Am J Clin Oncol.
1990;
13
427-432
- 74
Cho K H, Hall W A, Gerbi B J, Higgins P D, Bohen M, Clark H B.
Patient selection criteria for the treatment of brain metastases with sterotactic
radiosurgery.
J Neurooncol.
1998;
40
73-86
- 75
Flickinger J C, Lunsford L D, Somaza S, Konziolka D.
Radiosurgery: its role in brain metastasis management.
Neurosurg Clin N Am.
1996;
7
497-504
- 76
Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll H-J.
Diagnostisches und therapeuptisches Management der oberen Einflussstauung.
Med Klinik.
1999;
94
681-684
- 77
Markman M.
Diagnosis and management of superior vena cava syndrome.
Cleve Clin J Med.
1999;
66
59-61
- 78
Ostler P J, Clarke D P, Watkinson A F, Gaze M N.
Superior vena cava obstruction: a modern management strategy.
Clin Oncol R Coll Radiol.
1997;
9
83-89
- 79
Hochrein J, Bashore T M, O'Laughin M P, Harrison K.
Percutaneous stenting of superior vena cava syndrome: a case report and review of
theliterature.
Am J Med.
1998;
104
78-84
- 80 Nesbitt J C. Surgical management of superior vena cava syndrome. In: Pass HJ, Mitchell
JB, Johnson DH, Turrisi AT (eds). Lung Cancer. Principles and Practice Philadelphia-New
York: Lippincott-Raven 1996: 671-681
- 81
Byrne T N.
Spinal cord compression from epidural metastases.
N Engl J Med.
1992;
327
614-619
- 82
Soerensen S, Helweg-Larsen S, Mouridsen H, Hansen H H.
Effect of high-dose dexamethasone in carcinomateous metastatic spinal cord compression
treated with radiotherapy: a randomised trial.
Eur J Cancer.
1994;
30A
22-27
- 83
Bach F, Agerlin N, Sorensen J B, Rasmussen T B, Dombernowsky P, Sorensen P S, Hansen H H.
Metastatic spinal cord compression secondary to lung cancer.
J Clin Oncol.
1992;
10
1781-1787
- 84
Loblaw D A, Laperriere N J.
Emergency treatment of malignant extradural spinal cord compression: an evidence-based
guideline.
J Clin Oncol.
1998;
16
1613-1624
- 85
Maranzano E, Latini P.
Effectiveness of radiation therapy without surgery in metastatic spinal cord compression:
final results from a prospective trial.
Int J Radiat Oncol Biol Phys.
1995;
32
959-967
- 86
Solberg A, Bremnes R M.
Metastatic spinal cord compression: diagnostic delay, treatment, and outcome.
Anticancer Res.
1999;
19
677-684
- 87
Loddenkemper R.
Thoracoscopy - state of the art.
Eur Respir J.
1998;
11
213-221
- 88
Rodriguez-Panadero F, Antony V B.
Pleurodesis: state of the art.
Eur Respir J.
1997;
10
1648-1654
- 89
Hentrich M, Hartenstein R.
Behandlung maligner Körperhöhlenergüsse.
Internist.
1997;
38
794-804
- 90
Waller D A, Morritt G N, Forty J.
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
Chest.
1995;
107
1454-1456
- 91
Berg M, Heisel A, Ukena D, Schäfers H-J, Schieffer H.
Behandlung des malignen Perikardergusses.
Med Klinik.
1997;
92
27-30
- 92
Cherny N I, Portenoy R K.
The management of cancer pain.
CA Cancer J Clin.
1994;
44
263-303
- 93
World Health Organization [WHO] .
Cancer pain relief. With a guide to opioid availability.
Cancer Pain Relief.
1996;
1-63
- 94
Zech D F, Grond S, Lynch J, Hertel D, Lehmann K A.
Validation of World Health Organization guidelines for cancer pain relief. A 10-year
prospective study.
Pain.
1995;
63
65-76
- 95
Bone Pain Trial Working Party .
8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized
comparison with a multifraction schedule over 12 months of patient follow-up.
Radiother Oncol.
1999;
52
111-121
- 96
Reichle G, Freitag L, Kullmann H J, Prenzel R, Macha H N, Farin G.
Argon plasma coagulation in bronchology: a new method - alternative or complementary.
J Bronchol.
2000;
7
109-117
- 97
Medical Research Concil Lung Cancer Working Party .
A Medical Research Council (MRC) randomized trial of palliative radiotherapy with
two fractions or a single fraction in patients with inoperable non-small-cell lung
cancer (NSCLC) and poor performance status.
Br J Cancer.
1992;
65
934-941
- 98
Medical Research Concil Lung Cancer Working Party .
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy
for patients with inoperable non-small-cell lung cancer and good performance status.
Clinical Oncol.
1996;
8
167-175
- 99
Speiser B L, Spratling L.
Remote afterloading brachytherapy for the local control of endobronchial carcinoma.
Int J Radiation Oncology Biol Phys.
1993;
25
579-587
- 100
Freitag L, Tekolf E, Stamatis G, Montag M, Greschuchna D.
Three years experience with a new balloon catheter for the management of hemoptysis.
Europ Res J.
1994;
7
2033-2037
- 101
Stoll J F, Bettmann M A.
Bronchial artery embolization to control hemoptysis: a review.
Cardiovasc Intervent Radiol.
1988;
11
263-269
- 102
Zhang J S, Cui Z P, Wang M Q, Yang L.
Bronchial arteriography and transcatheter embolization in the management of hemoptysis.
Cardiovasc Intervent Radiol.
1994;
17
276-279
- 103
Deutsche Gesellschaft für Pneumologie .
Empfehlungen zur bronchoskopischen Behandlung tracheobronchialer Verschlüsse, Stenosen
und muraler maligner Tumoren.
Pneumologie.
1998;
52
243-248
- 104
Mathissen D J, Grillo H C.
Endoscopic relief of malignant airway obstruction.
Ann Thorac Surg.
1998;
48
469-475
- 105
Cavaliere S, Foccoli P, Tonielli C, Feijo S.
Nd-YAF laser therapy in lung cancer. An 11 year experience with 2253 applications
in 1585 patients.
J Bronchol.
1994;
1
105-111
- 106
Macha H N, Becker K O, Kemmer H P.
Pattern of failure and survival in endobronchial laser resection: a matched pair study.
Chest.
1994;
105
1668-1672
- 107 Vergnon J M, Mathur P N. Cryotherapy for endobronchial disorders. In: Boliger
CT, Mathur PN (Hrsg). Interventional Bronchoscopy Prog Respir Res Basel: Karger 2000
Vol 30: 133-145
- 108
Sutedja G, van Boxem T J, Schramel F M, Felius v C, Postmus P E.
Endobronchial electrocautery is an excellent alternative for Nd: YAG laser to treat
airway tumors.
J Bronchol.
1997;
4
101-105
- 109 Sutedja G, Bolliger C. Endothelial electrocautery and argon plasma coagulation. In:
Bolliger CT, Mathur PN (Hrsg). Interventional Bronchoscopy Prog Respir Res Basel:
Karger 2000 30: 120-132
- 110 Maiwand M O, Homasson J P. Cryotherapy for tracheobronchial disorders. In: Mathur
PN, Beamis JF (Hrsg). Clinics in Chest Medicine Philadelphia: Saunders 1995 Vol 16:
427-443
- 111
Sutedja T G, Postmus P E.
Photodynamic therapy in lung cancer. A review.
J Photochem Photobiol B.
1996;
36
199-204
- 112
Freitag L, Korupp A, Itzigehl I, Dankwart F, Tekolf E, Reichle G, Kullmann H J, Macha H N.
Erfahrungen mit Fluoreszenzdiagnostik und photodynamischer Therapie im multimodalen
Behandlungskonzept des operierten rezidivierenden Bronchialkarzinoms.
Pneumologie.
1996;
50
693-699
- 113
George P JM, Garrett C PO, Nixon C, Hetzel M R, Nanson E M, Millard F J.
Laser treatment for tracheobronchial tumors: local or general anesthesia?.
Thorax.
1987;
42
656-660
- 114
Macha H N, Wahlers B, Reichle G, von Zwehl D.
Endobronchial radiation therapy for obstructing malignancies: ten years' experience
with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients.
Lung.
1995;
173
271-280
- 115
Huber R M, Fischer R, Hautmann H, Pollinger B, Wendt T, Müller-Wening D, Häussinger K.
Palliative endobronchial bradytherapy for central lung tumors. A prospective, randomized
comparison of two fractionation schedules.
Chest.
1995;
107
463-470
- 116
Huber R M, Fischer R, Hautmann H, Pollinger B, Häussinger K, Wendt T.
Does additional brachytherapy improve the effect of external irradiation? A prospective,
randomized study in central tumors.
Int J Radiat Oncol Biol Phys.
1997;
38
533-540
- 117 Freitag L. Tracheobronchial stents. In: Bolliger CT, Mathur PN (Hrsg). Interventional
Bronchoscopy Pro Respir Res Basel: Karger 2000 30: 171-186
- 118
Sutedja G, Schramel F, van Kralingen K, Postmus P E.
Stent placement is justifiable in endstage patients with malignant airway tumors.
Respiration.
1995;
62
148-150
- 119
Silvestri G A, Handy J, Lackland D, Corley E, Reed C E.
Specialists achieve better outcomes than generalists for lung cancer surgery [see
comments].
Chest.
1998;
114
675-680
- 120
Duque J L, Ramos G, Castrodeza J, Cerezal J, Castanedo M, Yuste M G, Heras F.
Early complications in surgical treatment of lung cancer: a prospective, multicenter
study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia
y Cirugia Toracica.
Ann Thorac Surg.
1997;
63
944-950
- 121
Ginsberg R J, Hill L D, Eagan R T, Thomas P, Mountain C F, Deslauriers J, Fry W A,
Butz R O, Goldberg M, Waters P F.
Modern thirty-day operative mortality for surgical resections in lung cancer.
J Thorac Cardiovasc Surg.
1983;
86
654-658
- 122
Warren W H, Faber L P.
Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma.
J Thorac Cardiovasc Surg.
1994;
107
1087-1094
- 123
Wahi R, McMurtrey M J, DeCaro L F, Mountain C F, Ali M K, Smith T L, Roth J A.
Determinants of perioperative morbidity and mortality after pneumonectomy.
Ann Thorac Surg.
1989;
48
33-37
- 124
Klemperer J, Ginsberg R J.
Morbidity and mortality after pneumonectomy.
Chest Surg Clin N Am.
1999;
9
515-525
- 125
Gaissert H A, Mathisen D J, Moncure A C, Hilgenberg A D, Grillo H C, Wain J C.
Survival and function after sleeve lobectomy for lung cancer.
J Thorac Cardiovasc Surg.
1996;
111
948-953
- 126
Bach P, Cramer L, Schrag D, Downey R, Gelfand S, Begg C.
The influence of hospital volume on survival after resection of lung cancer.
N Engl J Med.
2001;
345
181-188
- 127
Sugi K, Kaneda Y, Esato K.
Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis
in patients with clinical stage IA lung cancer.
World J Surg.
2000;
24
27-30
- 128
Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H.
Lymph node sampling in lung cancer: how should it be done?.
Eur J Cardiothorac Surg.
1999;
16 Suppl 1
S17-S24
- 129
McKenna-RJ J, Wolf R K, Brenner M, Fischel R J, Wurnig P.
Is lobectomy by video-assisted thoracic surgery an adequate cancer operation?.
Ann Thorac Surg.
1998;
66
1903-1908
- 130
Mack M J, Scruggs G R, Kelly K M, Shennib H, Landreneau R J.
Video-assisted thoracic surgery: has technology found its place?.
Ann Thorac Surg.
1997;
64
211-215
- 131
Bernard A.
Resection of pulmonary nodules using video-assisted thoracic surgery. The Thorax Group.
Ann Thorac Surg.
1996;
61
202-204
- 132
Mountain C, Dresler C.
Regional lymphnode classification for lung cancer staging.
Chest.
1997;
111
1718-1723
- 133
Passlick B, Thetter O.
Lymph node documentation and lymphadenectomy in bronchial carcinomas. Results of a
survey in Germany.
Chirurg.
1997;
68
601-605
- 134
Schildberg F W, Dienemann H, Hoffmann H.
Lymphadenektomie bei Bronchialkarzinomen: Fakten und Fiktion.
Zentralbl.
1996;
121
96-101
- 135
Izbicki J R, Thetter O, Habekost M, Karg O, Passlick B, Kubuschok B, Busch C, Haeussinger K,
Knoefel W T, Pantel K.
Radical systematic lymphadenectomy in non-small cell lung cancer - A prospective controlled
randomized clinical trial.
Brit J Surg.
1994;
81
229-235
- 136
Izbicki J R, Passlick B, Pantel K, Pichlmeier U, Hosch S B, Karg O, Thetter O.
Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable
non-small cell lung cancer - Results of a prospective randomized study.
Ann Surg.
1998;
227
138-144
- 137
Luketich J D, Burt M E.
Does resection of adrenal metastases from non-small-cell lung cancer improve survical?.
Ann Thorac Surg.
1996;
62
1614-1616
- 138
Mussi A, Pistolesi M, Lucchi M. et al .
Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors.
J Thorac Cardiovasc Surg.
1996;
112
146-153
- 139
Porte H L, Roumilhac D, Graziana J P. et al .
Adrenalectomy for a solitary adrenal metastasis form lung cancer.
Ann Thorac Surg.
1998;
65
331-335
- 140
Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H.
Implications of staging in lung cancer.
Chest.
1997;
112
242S-248S
- 141
Mountain C F.
The biological operability of stage III non-small cell lung cancer.
Ann Thorac Surg.
1985;
40
60-64
- 142
Inoue K, Sato M, Fujimara S, Sakurada A, Takahashi S, Usuda K, Kondo T, Tanita T,
Handa M, Saito Y.
Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent
complete resection from 1980 to 1993.
J Thorac Cardiovasc Surg.
1998;
116
407-411
- 143
Sagawa M, Sakurada A, Fujimara S, Sato M, Takahashi S, Usuda K, Endo C, Aikawa H,
Kondo T, Saito Y.
Five-year survivors with resected pN2 nonsmall cell lung carcinoma.
Cancer.
1999;
85
864-868
- 144
Kreisman H, Wolkove N, Quoix E.
Small cell lung cancer presenting as a solitary pulmonary nodule.
Chest.
1992;
101
225-231
- 145
Fujimori K, Yokoyama A, Kurita Y, Terashima M.
A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable
stage I to IIIA small cell lung cancer.
Chest.
1997;
111
1089-1093
- 146
Elias A D.
Small cell lung cancer: state-of-the-art therapy in 1996.
Chest.
1996;
112
251S-258S
- 147
Osterlind K, Hansen M, Hansen H H, Dombernowsky P, Rorth M.
Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis
of a series of 874 consecutive patients.
Thorax.
1985;
40
272-277
- 148
Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G.
A prospective randomized trial to determine the benefit of surgical resection of residual
disease following response of small cell lung cancer to combination chemotherapy.
Chest.
1994;
106
320S-323S
- 149
Fox W, Scadding J G.
Medical Research Council comparative trial of surgery and radiotherapy for primary
treatment of small-celled or oat-cell carcinoma of bronchus. Ten-year follow-up.
Lancet.
1973;
2
63-65
- 150
Müler L C, Salzer G M, Huber H, Prior C, Ebner I, Frommhold H, Prauer H W.
Multimodal therapy of small cell lung cancer in TNM stages I through IIIa.
Ann Thorac Surg.
1992;
54
493-497
- 151
Eberhardt W, Stamatis G, Stuschke M, Wilke H, Muller M R, Kolks S, Flasshove M, Schutte J,
Stahl M, Schlenger L, Budach V, Gerschuchna D, Stuben G, Teschler H, Sack H, Seeber S.
Prognostically orientated multimodality treatment including surgery for selected patients
of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase
II trial.
Br J Cancer.
1999;
81
1206-1212
- 152
Armstrong J.
Target volume definition for three-dimensional conformal radiation therapy of lung
cancer.
Br J Radiol.
1998;
71
587-594
- 153
Graham M V, Prudy J A, Emamai B, Harms W, Bosch W, Lockett M A, Perez C A.
Clinical dose-volume histogramm analysis for pneumonitis after 3D treatment for non-small
cell lung cancer (NSCLC).
Int J Radiat Oncol Biol Phys.
1999;
45
323-329
- 154
Marks L, Munley M T, Bentel G C, Zhou S M, Hollis D, Scarfone C, Sibley G, Kong F M,
Jirtle R, Jaszczak R, Coleman R E, Tapson V, Anscher M.
Physical and biological predictors of changes in whole lung function following thoracic
irradiation.
Int J Radiat Oncol Biol Phys.
1997;
39
563-570
- 155
Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, Kutcher G, Harrison L,
Hahn C, Ginsberg R, Rusch V, Kris M, Fuks Z.
Promising survival with three-dimensional conformal radiation therapy for non-small
cell lung cancer.
Radiother Oncol.
1997;
44
17-22
- 156
De Ruysscher D, Vansteenkiste J.
Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.
Radiother Oncol.
2000;
55
1-9
- 157
Royal College of Radiologists .
Guidelines on the non-surgical management of lung cancer.
Clinical Oncology.
1999;
11
S1-S53
- 158
Cox J, Azarnia N, Byhardt R W, Shin K H, Emami B, Pajak T F.
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses
of 60.0 Gy to 79.3 Gy: possible survival benefit with greater than or equal to 69.6
Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell
lung carcinoma: report of Radiation Therapy Oncology Group 83 - 11.
J Clin Oncol.
1990;
9
1543-1555
- 159
Appold S, Baumann M, Neidt F, Herrmann T.
Ergebnisse der Bestrahlung inoperabler nichtkleinzelliger Bronchialkarzinome im Stadium
III mit 25 Gy in fünf Fraktionen.
Strahlenther Onkol.
1999;
175
267-270
- 160
McQuay H J, Collins S L, Carroll D, Moore R A.
Radiotherapy for the palliation of painful bone metastases.
Cochrane Database Syst Rev.
2000;
CD001793
- 161
Coia L R, Aaronson N, Linggood R, Loeffler J, Priestman T J.
A report of the consensus workshop panel on the treatment of brain metastases.
Int J Radiat Oncol Biol Phys.
1992;
23
223-227
- 162
Koswig S, Budach V.
Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter
Strahlentherapie (10mal 3 Gy vs. 1 mal 8 Gy).
Strahlentherapie Onkol.
1999;
175
500-508
- 163
Nestle U, Nieder C, Walter K, Abel U, Ukena D, Sybrecht G W, Schnabel K.
A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer
vs. Conventionally fractionated 60 Gy: results of a randomized equivalence study.
Int J Radiat Oncol Biol Phys.
2000;
48
95-103
- 164
Steenland E, Leer J, van Houwelingen H, Post W J, van den Hout W B, Kievit J, de Haes H,
Martijn H, Oei B, Vonk E, van der Stehen-Banasik E, Wiggenraad R GJ, Hoogenhout J,
Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo T,
Rutten E.
The effect of a single fraction compared to multiple fractions on painful bone metastases:
a global analysis of the Dutch bone metastasis study.
Radiother Oncol.
1999;
52
101-109
- 165
Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H, Heim M, Hruska D, Mende S,
Becker H, Dannhäuser J, Lohmüller R, Gropp C, Gassel W D, Holle R, Havemann K.
Cyclic-alternating versus response-oriented chemotherapy in small-cell-lung cancer:
a German multicenter randomized trial of 321 patients.
J Clin Oncol.
1991;
9
614-624
- 166
Murray N, Livingston R B, Shepherd F A, James K, Zee B, Langleben A, Kraut M, Bearden J,
Goodwin J W, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell
lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clincial
Trials Group and the Southwest Oncology Group.
J Clin Oncol.
1999;
8
2300-2308
- 167
Souhami R L, Rudd R, Ruiz de Elvira M C, James L, Gower N, Harper P G, Tobias J S,
Partridge M R, Davison A G, Trask C, Spiro S G.
Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer:
a Cancer Research Campaign trial.
J Clin Oncol.
1994;
12
1806-1813
- 168
Arriagada R, Le Chevalier T, Pignon J P, Riviere A, Monnet I, Chomy P, Tuchais C,
Tarayre M, Ruffie P.
Initial chemotherapeutic doses and survival in patients with limited small-cell lung
cancer.
N Engl J Med.
1993;
329
1848-1852
- 169
Johnson D H, Carbone D P.
Increased Dose-Intensity in Small-Cell Lung Cancer: A Failed Strategy?.
J Clini Oncol.
1999;
17
2297-2298
- 170
Chute J P, Chen T, Feigal E, Simon R, Johnson D.
Twenty years of Phase III Trials for Patients with Extensive-Stage Small-Cell Lung
Cancer. Perceptible Progress.
J Clin Oncol.
1999;
17
1794-1801
- 171
Kosmidis P A, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D.
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small
cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group
for Lung Cancer Trials.
Semin Oncol.
1994;
21
23-30
- 172
Medical Research Council Lung Cancer Working Party .
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell
lung cancer. A stopped multicentre randomised trial.
Lancet.
1996;
348
563-566
- 173
Medical Research Council Lung Cancer Working Party .
Randomised trial of four-drug versus less intensive two-drug chemotherapy in the palliative
treatment of patients with small cell lung cancer (SCLC) and poor prognosis.
B J Cancer.
1996;
73
406-413
- 174
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G,
Schaefer B, Wanders J, Verweij J.
Topotecan an new drug in the second-line treatment of small-cell lung cancer: A phase
II study of patients with refractory and sensitive disease.
J Clin Oncol.
1997;
15
2090-2096
- 175
Groen H JM, Fokkema E, Biesma B, Kwa B, van Putten J WG, Postmus P E, Smit E F.
Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant
to Cyclophosphamide, Doxorubicin, and Etoposide: A Non-Cross-Resistant Schedule.
J Clin Oncol.
1999;
17
927-932
- 176
von Pawel J, Schiller J H, Shephard F A, Fields S Z, Kleisbauer J P, Chrysson N G,
Stewart D J, Clark P I, Palmer M C, Depierre A, Carmichael J, Krebs J B, Ross G, Lane S R,
Gralla R.
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment
of Recurrent Small-Cell lung Cancer.
J Clin Oncol.
1999;
17
658-667
- 177
Masuda N, Matusi K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T,
Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M.
Combination of Irinotecan and Etoposide for treatment of refractory or relapsed small
cell lung cancer.
J Clin Oncol.
1998;
16
3329-3334
- 178 Ginsberg R, Vokes E, Raben A. Non-small cell lung cancer. In: DeVita V, Hellman
S, Rosenberg S (Hrsg). Cancer Philadelphia: Lippincott-Raven 1997: 858
- 179
Marino P, Preatoni A, Cantoni A, Bucceri G.
Single-agent chemotherapy versus combination chemotherapy in advanced NSCLC. A quality
and meta-analysis study.
Lung Cancer.
1995;
13
1-12
- 180
Lilienbaum R C, Langenberg P, Dickersin K.
Single agent chemotherapy versus combination chemotherapy in patients with advanced
NSCLC: A meta-analysis of response, toxicity and survival.
Cancer.
1998;
82
116-126
- 181
Perng R P, Chen Y M, Ming-Liu J, Tsai C M, Lin W C, Yang K Y, Whang-Peng J.
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable
non-small-cell lung cancer in a phase II randomized study.
J Clin Oncol.
1997;
15
2097-2102
- 182
Manegold C, Bergmann B, Chemaissani A, Dornhoff W, Drings P, Kellokumpu-Lehtinen P,
Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel R A, Wagenius G, van
Walree N, ten Bokkel-Huinink W.
Single agent gemcitabine versus cisplatin-etoposide: early results of a randomized
phase II study in locally advanced or metastatic non-small cell lung cancer.
Ann Oncol.
1997;
8
525-529
- 183
Frasci G, Lorusso V, Panza N, Comella P, Nicollela G, Bianco A, De Cataldis G, Ianelli A,
Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Iena M.
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced
NSCLC.
J Clin Oncol.
2000;
18
2529-2536
- 184
The Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS) .
Effects of vinorelbine on quality of life and survival of elderly patients with advanced
non-small-cell lung cancer.
J Natl Cancer Inst.
1999;
91
66-72
- 185
Larsen H, Sörensen J B, Nielsen A L, Dombernowsky P, Hansen H.
Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable
NSCLC.
Ann Oncol.
1995;
6
993-997
- 186
Smith I E, O'Brien M ER, Norton A, Ashley S, Webb A, Nicolson M, Hickish T, Talbot T,
Mansi J.
Duration of chemotherapy for advances NSCLC: A phase III randomized trial of 3 versus
6 courses of mitomycin, vinblastine, cisplatin (MVP).
Proc Am Soc Clin Oncol.
1998;
(abs. 1759)
- 187
Giaccone G, Splinter T A, Debruyne C, Kho G S, Lianes P, van Zandwijk N, Penucci M C,
Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus P E.
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with
advanced non-small-cell lung cancer. The European Organization for Research and Treatment
of Cancer Lung Cancer Cooperative Group.
J Clin Oncol.
1998;
16
2133-2141
- 188
Cardenal F, Lopez-Cabrerizo P, Anton A, Rosell R.
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in
the treatment of locally advanced or metastatic NSCLC.
J Clin Oncol.
1999;
17
12-18
- 189
Le Chevalier T, Brisgand D, Douillard J, Pujol J, Alberola V, Monnier A, Riviere A,
Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard M, Ravaioli A,
Besenval M, Besson F, Martinez A, Berthaud P, Tursz T.
Randomized study of Vinorelbine and Cisplatin versus Vindesine and Cisplatin versus
Vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter
trial including 612 patients.
J Clin Oncol.
1994;
12
360-367
- 190
Klasterski J, Sculier J, Lacoix H. et al .
A randomized study comparing cisplatin or Carboplatin with etoposide in patients with
advanced NSCLC. EORTC Protocol 07861.
J Clin Oncol.
1990;
8
1556-1562
- 191
Biesma B, Smit E F, Postmus P E.
A dose and schedule finding study of gemcitabine and etoposide in patients with progressive
NSCLC after platinum containing chemotherapy.
Lung Cancer.
1999;
24
115-121
- 192
Fossella F, DeVore R, Kerr R, Crawford J, Natale R, Dunphy F, Kalman L, Miller V,
Lee J, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza S, Hammershaimb L. and the
TAX 320 non-small cell lung cancer study group .
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients
with advanced non-small cell lung cancer previously treated with platinum-containing
chemotherapy regimens.
J Clin Oncol.
2000;
18
2354-2362
- 193
Shepherd F A, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L,
Vincent M, Burkes R, Coughlin S, Kim Y, Berille J.
Prospective randomized trial of Docetaxel versus best Supportive Care in patients
with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
J Clin Oncol.
2000;
18
2095-2103
- 194
Sutedja G, Postmus P E.
Bronchoscopic treatment of lung tumors.
Lung cancer.
1994;
11
1-117
- 195
Venmans B J, van Boxem T J, Smit E F, Postmus P E, Sutedja T G.
Outcome of bronchial carcinoma in situ.
Chest.
2000;
117
1572-1576
- 196
Sheski F D, Mathur P N.
Endoscopic treatment of early-stage lung cancer.
Cancer Control.
2000;
7
35-44
- 197
Koike T, Terashima M, Takizawa T, Tsukada H, Yokoyama A, Kurita Y, Honma K.
Surgical results for centrally-located early stage lung cancer.
Ann Thorac Surg.
2000;
70
1176-1179
- 198
Johnson B E.
Second lung cancer in patients after treatment for an initial lung cancer.
J Natl Cancer Inst.
1998;
90
1335-1345
- 199
Edell E S, Cotese D A.
Photodynamic therapy in the management of early superficial squamous cell carcinoma
as an alternative to surgical resection.
Chest.
1992;
102
1319-1322
- 200
Perol M, Caliandro R, Pommier P, Malet C, Montbarbon X, Carrie C, Ardiet J M.
Curative irradiation of limited carcinomas with high-dose brachytherapy.
Chest.
1997;
111
1417-1423
- 201
van Boxem T J, Venmans B J, Schramel F M, van Mourik J C, Golding R P, Postmus P E,
Sutedja T G.
Radiographically occult lung cancer treated with fibreoptic bronchoscopic electrocautery:
a pilot study of a simple and inexpensive technique.
Eur Respir J.
1998;
11
169-172
- 202
Deygas N, Froudarakis M E, Ozenne G, Jouve S, Fournel P, Vergnon J M.
Cryotherapy in early superficial bronchogenic carcinoma.
Eur Respir J.
1998;
12 (Suppl 28)
266
- 203
Furuse K, Fukuoka M, Kato H, Horrai T, Kubota T, Kodama N, Kusunoki Y, Takifuji N,
Okunaka T, Konaka C, Wada H, Hayata Y.
A prospective phase II study on photodynamic therapy with photofrin II for centrally
located early-stage lung cancer.
J Clin Oncol.
1993;
11
1852-1857
- 204
Kato H, Okunaka T, Shimatani H.
Photodynamic therapy for early stage bronchogenic carcinoma.
J Clin Laser Med Surg.
1996;
14
235-238
- 205
Cortese D A, Edell E S, Kinsey J H.
Photodynamic therapy for early stage squamous cell carcinoma of the lung.
Mayo Clin Proc.
1997;
72
595-602
- 206
Martini N.
Surgical treatment of non-small cell lung cancer by stage.
Semin Surg Oncol.
1990;
6
248-254
- 207
Kotlyarov E, Rukosuyev A A.
Long-term results and patterns of disease recurrence after radical operations for
lung cancer.
J Thorac Cardiovasc Surg.
1991;
102
24-28
- 208
The Lung Cancer Study Group .
Patterns of failure in patients with resected stage I und II non-small cell carcinoma
of the lung.
Ann Surg.
1987;
205
67
- 209
Pairolero P C, Williams D E, Bergstralh E J, Piehler J M, Bernatz P E, Payne W S.
Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease.
Ann Thorac Surg.
1984;
38
331-338
Priv.-Doz. Dr. med. M. Thomas
Klinik für Hämatologie, Onkologie und Pneumologie Medizinische Klinik A, Universitätsklinikum
Münster
Albert-Schweizer Str. 33
48149 Münster
eMail: mthomas@uni-muenster.de